MarketCap
Facebook
X
Telegram
Zynerba Pharmaceuticals Operativer Cashflow | ZYNE
Operativer Cashflow Jährlich Zynerba Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -23 M | -33.5 M | -41.3 M | -34.8 M | -32.4 M | -25.8 M | -20.4 M | -9.79 M | -3.54 M | -118 K | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| -118 K | -41.3 M | -22.5 M |
Operativer Cashflow Vierteljährlich Zynerba Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -16.3 M | -7.88 M | - | -17.3 M | -7.68 M | 201 K | - | -25.6 M | -15.6 M | -8.29 M | - | -34.3 M | -21.7 M | -11 M | - | -27.4 M | -16.4 M | -9.52 M | - | -26.2 M | -19.3 M | -10.4 M | - | -19.1 M | -15.3 M | -7.65 M | - | -14.9 M | -9.35 M | -4.67 M | - | -6.59 M | -3.49 M | -1.92 M | - | -2.07 M | -650 K | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 201 K | -34.3 M | -12.9 M |
Operativer Cashflow anderer Aktien in der Arzneimittelhersteller
| Name | Operativer Cashflow | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
ProPhase Labs
PRPH
|
-8.34 M | - | - | $ 5.07 M |  USA |
 |
Endo International plc
ENDP
|
435 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-5.46 M | - | - | $ 36.6 M | USA |
 |
HEXO Corp.
HEXO
|
-117 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-435 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
-11.4 M | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
-19.1 M | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-25.9 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-99.2 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-9.58 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
-14.3 M | - | - | $ 142 M | USA |
 |
OrganiGram Holdings
OGI
|
3.87 M | $ 0.93 | 1.64 % | $ 88.6 M | Canada |
 |
Athenex
ATNX
|
-131 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-46.9 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
268 M | - | - | $ 11.5 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.93 M | $ 1.14 | -1.72 % | $ 1.92 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
50.7 M | - | -39.89 % | $ 27.7 M | USA |
 |
Cronos Group
CRON
|
25.9 M | $ 2.81 | 2.55 % | $ 1.08 B | Canada |
 |
TherapeuticsMD
TXMD
|
-159 M | $ 2.06 | - | $ 23.8 M | USA |
 |
Jupiter Wellness
JUPW
|
-6.4 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
-7.12 M | - | 1.15 % | $ 7.11 M | USA |
 |
Canopy Growth Corporation
CGC
|
-63.8 M | $ 0.89 | -1.82 % | $ 265 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
4.93 M | $ 6.61 | -5.37 % | $ 98.2 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-77.2 M | - | - | $ 193 M | Canada |
 |
Assertio Holdings
ASRT
|
-28.2 M | - | - | $ 150 M | USA |
 |
Radius Health
RDUS
|
-22.4 M | - | - | $ 1.42 B | USA |
 |
PetIQ
PETQ
|
61.9 M | - | 1.64 % | $ 400 M | USA |
 |
Recro Pharma
REPH
|
-1 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
-44.7 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
-32.1 M | - | -27.8 % | $ 2.56 M | USA |
 |
Zomedica Corp.
ZOM
|
-17.6 M | - | -0.21 % | $ 98 M | USA |
 |
Tricida
TCDA
|
-140 M | - | - | $ 3.25 M | USA |
 |
Perrigo Company plc
PRGO
|
238 M | $ 10.09 | -0.1 % | $ 1.4 B | USA |
 |
Bausch Health Companies
BHC
|
1.4 B | $ 4.43 | -0.45 % | $ 1.64 B | Canada |
 |
Emergent BioSolutions
EBS
|
171 M | $ 7.26 | -3.2 % | $ 388 M | USA |
 |
China Pharma Holdings
CPHI
|
148 K | $ 1.52 | -18.28 % | $ 6.52 M |  China |
 |
Aurora Cannabis
ACB
|
16 M | $ 2.67 | -0.74 % | $ 146 M | Canada |
 |
Harrow Health
HROW
|
43.9 M | $ 38.45 | -8.19 % | $ 1.41 B | USA |
 |
SCYNEXIS
SCYX
|
-5.28 M | $ 3.73 | -5.81 % | $ 186 M | USA |
 |
Evolus
EOLS
|
-42.3 M | $ 5.98 | -0.17 % | $ 386 M | USA |
 |
Rockwell Medical
RMTI
|
-659 K | $ 6.63 | 1.61 % | $ 239 M | USA |
 |
Solid Biosciences
SLDB
|
-156 M | $ 7.83 | -1.88 % | $ 685 M | USA |
 |
Relmada Therapeutics
RLMD
|
-45.8 M | $ 5.18 | -0.38 % | $ 205 M | USA |
 |
Veru
VERU
|
-30 M | $ 2.25 | -2.6 % | $ 33 M | USA |
 |
Organogenesis Holdings
ORGO
|
-10.3 M | $ 2.39 | -1.65 % | $ 303 M | USA |
 |
Pacira BioSciences
PCRX
|
189 M | $ 25.88 | -0.19 % | $ 1.2 B | USA |
 |
Sundial Growers
SNDL
|
70.9 M | $ 1.25 | -0.4 % | $ 323 M | Canada |
 |
cbdMD
YCBD
|
-1.45 M | $ 0.54 | -6.6 % | $ 2.17 M | USA |
 |
Tilray
TLRY
|
7.91 M | $ 3.88 | -2.76 % | $ 2.4 B | Canada |